STAT

Opinion: An opioid shortage? It’s real and could harm cancer patients

Managing symptoms at the end of life are an important part of a person's journey with cancer. Opioids are an essential part of that management.

Most doctors and health policy experts these days are focused on the overabundance of pills fueling the opioid crisis gripping the United States. Cancer doctors like me lie awake at night worrying about the looming shortage of injectable opioids that we need to treat our in-pain and dying patients.

Patients like Tommy Hogan (all of the names in this article have been changed to protect patients’ identities). At age 40, he was diagnosed with lung cancer, even though he never smoked. Despite the best efforts of his medical team, the cancer continued to grow and spread to other parts of his body. Two years later, Tommy was in a home hospice program.

A few days

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks